Helus Pharma’s Loss Widens to $103.091 Million as Phase 3 Data Looms
Key Facts
Helus Pharma reported results on November 16, 2026, for its fiscal second quarter ended September 30, posting a net loss of $103.091 million, compared with $33.722 million in the same period of 2025, according to its filing with the U.S. Securities and Exchange Commission. The results came as investors awaited preliminary efficacy data from the Phase 3 APPROACH trial of HLP003 for depression. The company had announced that Chief Executive Michael Halstead would present the data in a webcast at 8:00 a.m. Eastern Time that day. The results show the annual loss widening alongside increased clinical development spending and the recording of substantial share-based compensation expense. The company set the fourth quarter of 2026 as the target for reading out the trial results.
Operating expenses totaled $104.519 million for the quarter, compared with $28.894 million a year earlier. The figure included $64.961 million in non-cash share-based compensation, compared with $377 thousand in the same quarter of 2025. The company attributed part of the increase to compensation events during the quarter, including accelerated vesting of restricted stock units. This resulted in the recognition of $15.425 million in previously unrecognized share-based compensation expense. Non-cash compensation was therefore a major contributor to the rise in reported expenses, alongside spending on research and development programs.
Research expenses rose to $30.270 million from $18.850 million in the same period a year earlier. The company said the increase was particularly related to the progress of HLP003’s Phase 3 trials. Enrollment of 223 participants in the APPROACH trial was completed in July 2026. Participants were randomized to receive either a 16 mg dose of the drug or a placebo, with two doses three weeks apart. The study is testing the drug as an adjunctive treatment for patients with moderate to severe depression who do not respond adequately to stable antidepressant treatment, while its primary endpoint measures symptom change six weeks after the first dose.
Cash stood at $171.071 million on September 30, 2026, compared with $157.258 million on March 31. The company said its current resources were sufficient to meet current liabilities of $17.886 million, but noted that its operations had historically recorded negative operating cash flows. The company expects to need additional financing through equity, loans, partnerships and other means as it remains in the clinical development stage and had not marketed any products as of the report date. It also said its operations would not generate sufficient cash in the near term. In June 2026, it raised a total of $50 million through an offering of 10,309,280 shares at $4.85 per share, and sold 3.1 million shares through its at-the-market program during the six months ended September, at an average of $13.30 per share for gross proceeds of $41.23 million.
The company has contractual obligations for studies that could require additional spending of up to $84.787 million over 24 months through September 2028, with payment timing tied to the availability of materials and completion of specified milestones. On development, the company continues to enroll participants in the EMBRACE trial and conduct activities in the EXTEND extension study, according to its filing. It is targeting the start of the Phase 2 HLP004 study, as a single-use treatment for generalized anxiety disorder, by the end of the first quarter of 2027. Against the backdrop of management changes, the company appointed Halstead chief executive on August 3, 2026. Co-founders Eric So and Paul Glavin stepped down from their executive and advisory positions on October 27 while remaining on the board, and Mark Lawson was appointed independent board chair; HELP shares closed at $8.87 on November 13.